Close Menu

 NEW YORK (GenomeWeb) – Qiagen said today after the close of the market that the National Cancer Center (NCC) of Japan will use the Qiagen Clinical Insight (QCI) bioinformatics platform to analyze, interpret, and report molecular screening of cancer patients to help identify targeted therapies and clinical trial options.

Specifically, Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the NCC, will use the QCI platform to support its molecular profiling services for core and cooperative hospitals of Japan's national precision medicine program.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.